JP2014517808A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014517808A5 JP2014517808A5 JP2013558205A JP2013558205A JP2014517808A5 JP 2014517808 A5 JP2014517808 A5 JP 2014517808A5 JP 2013558205 A JP2013558205 A JP 2013558205A JP 2013558205 A JP2013558205 A JP 2013558205A JP 2014517808 A5 JP2014517808 A5 JP 2014517808A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- aryl
- halo
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 5
- 229910005965 SO 2 Inorganic materials 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 230000002132 lysosomal effect Effects 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 claims 2
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 102000005840 alpha-Galactosidase Human genes 0.000 claims 2
- 108010030291 alpha-Galactosidase Proteins 0.000 claims 2
- 125000005605 benzo group Chemical group 0.000 claims 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 108091000114 ceramide glucosyltransferase Proteins 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000009796 Gangliosidoses Diseases 0.000 claims 1
- 102000004547 Glucosylceramidase Human genes 0.000 claims 1
- 108010017544 Glucosylceramidase Proteins 0.000 claims 1
- 102000016871 Hexosaminidase A Human genes 0.000 claims 1
- 108010053317 Hexosaminidase A Proteins 0.000 claims 1
- 102000016870 Hexosaminidase B Human genes 0.000 claims 1
- 108010053345 Hexosaminidase B Proteins 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 125000003302 alkenyloxy group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000005466 alkylenyl group Chemical group 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000002641 enzyme replacement therapy Methods 0.000 claims 1
- 201000006440 gangliosidosis Diseases 0.000 claims 1
- 150000002339 glycosphingolipids Chemical class 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- -1 isopropenylphenyl Chemical group 0.000 claims 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161454034P | 2011-03-18 | 2011-03-18 | |
| US61/454,034 | 2011-03-18 | ||
| US201261590711P | 2012-01-25 | 2012-01-25 | |
| US61/590,711 | 2012-01-25 | ||
| PCT/US2012/029417 WO2012129084A2 (en) | 2011-03-18 | 2012-03-16 | Glucosylceramide synthase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017055577A Division JP6420860B2 (ja) | 2011-03-18 | 2017-03-22 | グルコシルセラミド合成酵素阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014517808A JP2014517808A (ja) | 2014-07-24 |
| JP2014517808A5 true JP2014517808A5 (enExample) | 2015-04-23 |
| JP6117708B2 JP6117708B2 (ja) | 2017-04-19 |
Family
ID=46879977
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013558205A Active JP6117708B2 (ja) | 2011-03-18 | 2012-03-16 | グルコシルセラミド合成酵素阻害剤 |
| JP2017055577A Active JP6420860B2 (ja) | 2011-03-18 | 2017-03-22 | グルコシルセラミド合成酵素阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017055577A Active JP6420860B2 (ja) | 2011-03-18 | 2017-03-22 | グルコシルセラミド合成酵素阻害剤 |
Country Status (39)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103917094B (zh) * | 2011-03-18 | 2016-11-09 | 建新公司 | 葡萄糖基神经酰胺合酶抑制剂 |
| AU2019222801B2 (en) * | 2012-09-11 | 2021-02-18 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| TW201900625A (zh) * | 2013-03-15 | 2019-01-01 | 美商健臻公司 | 製備葡糖基神經醯胺合成酶抑制劑之方法 |
| JO3713B1 (ar) * | 2013-03-15 | 2021-01-31 | Genzyme Corp | أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت |
| CN104418851A (zh) * | 2013-09-02 | 2015-03-18 | 上海龙翔生物医药开发有限公司 | 奎宁环衍生物的制备方法及纯化方法 |
| ES2871416T3 (es) * | 2013-12-11 | 2021-10-28 | Genzyme Corp | Inhibidores de glucosilceramida sintasa |
| JP6836502B2 (ja) * | 2014-05-30 | 2021-03-03 | スプハエラ ファーマ ピーヴィーティー リミテッド | 抗結核薬としての新規な化合物 |
| WO2016126572A2 (en) | 2015-02-02 | 2016-08-11 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| JP2018525345A (ja) | 2015-07-01 | 2018-09-06 | ノースウェスタン ユニバーシティ | 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用 |
| CN108290894A (zh) * | 2015-07-01 | 2018-07-17 | 西北大学 | 被取代的4-甲基-吡咯并[1,2-a]嘧啶-8-甲酰胺类化合物及其调节葡糖脑苷脂酶活性的用途 |
| AR107483A1 (es) * | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| JP6940515B2 (ja) * | 2016-03-25 | 2021-09-29 | ジェンザイム・コーポレーション | タンパク質症のバイオマーカーおよびその使用 |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| EP3538095A4 (en) | 2016-11-14 | 2020-06-17 | Berg LLC | Methods for treating parkinson's disease |
| EP3562821B9 (en) | 2016-12-28 | 2021-05-26 | Minoryx Therapeutics S.L. | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase |
| CA3048357A1 (en) | 2016-12-29 | 2018-07-05 | Minoryx Therapeutics S.L. | Heteroaryl compounds and their use |
| CN108341822B (zh) * | 2017-01-23 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和应用 |
| EP3709986B1 (en) * | 2017-11-14 | 2023-11-01 | Merck Sharp & Dohme LLC | Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| US20200339587A1 (en) | 2017-12-21 | 2020-10-29 | Lysosomal Therapeutics Inc. | Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof |
| JP7317721B2 (ja) * | 2018-01-31 | 2023-07-31 | 武田薬品工業株式会社 | 複素環化合物 |
| US10519157B2 (en) * | 2018-02-09 | 2019-12-31 | X-Cutag Therapeutics, Inc. | Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof |
| KR102342901B1 (ko) * | 2018-11-22 | 2021-12-24 | (주)프로스테믹스 | 엑소좀 및 이의 다양한 용도 |
| KR102342902B1 (ko) * | 2018-11-22 | 2021-12-24 | (주)프로스테믹스 | 엑소좀 및 이의 다양한 용도 |
| KR102233530B1 (ko) * | 2018-11-22 | 2021-03-31 | (주)프로스테믹스 | 엑소좀 및 이의 다양한 용도 |
| WO2020163244A1 (en) * | 2019-02-04 | 2020-08-13 | Genzyme Corporation | Methods for treating symptoms and disorders associated with lysosomal storage diseases |
| US12527776B2 (en) | 2019-02-04 | 2026-01-20 | Genzyme Corporation | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) |
| WO2020193746A1 (en) | 2019-03-28 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival of patients suffering from melanoma |
| JP7539382B2 (ja) * | 2019-07-29 | 2024-08-23 | 武田薬品工業株式会社 | 複素環化合物 |
| US11220479B2 (en) | 2019-10-23 | 2022-01-11 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| BR112022009409A2 (pt) | 2019-11-15 | 2022-08-09 | Yuhan Corp | Novos derivados que têm grupamento 2,3-dihidro-1h-indeno ou 2,3-dihidrobenzofurano ou sal farmaceuticamente aceitável dos mesmos e composições farmacêuticas que os compreendem |
| US20230002380A1 (en) * | 2019-11-15 | 2023-01-05 | Yuhan Corporation | Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same |
| BR112022010127A2 (pt) | 2019-11-25 | 2022-09-06 | Gain Therapeutics Sa | Compostos de arila e heteroarila e usos terapêuticos dos mesmos em condições associadas à alteração da atividade de galatocerebrosidase |
| BR112022010126A2 (pt) | 2019-11-25 | 2022-09-06 | Gain Therapeutics Sa | Compostos de heteroarila e usos terapêuticos dos mesmos em condições associadas à alteração da atividade da betaglucocerebrosidase |
| EP4100009A1 (en) * | 2020-02-03 | 2022-12-14 | Genzyme Corporation | Methods for treating neurological symptoms associated with lysosomal storage diseases |
| US20230140216A1 (en) | 2020-02-03 | 2023-05-04 | Gain Therapeutics Sa | Combination therapy for treating mps1 |
| WO2021214771A1 (en) | 2020-04-23 | 2021-10-28 | The Israel Institute of Biological Research (IIBR) | Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases |
| EP4142878B1 (en) | 2020-04-28 | 2024-06-26 | The Regents of The University of Michigan | Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same |
| KR20230043024A (ko) | 2020-07-24 | 2023-03-30 | 젠자임 코포레이션 | 벤글루스타트를 포함하는 제약 조성물 |
| MX2023001285A (es) * | 2020-07-30 | 2023-02-22 | Genzyme Corp | Metodos para reducir la concentracion de glicoesfingolipidos en el tejido cerebral y metodos de tratamiento de enfermedades neurodegenerativas que implican los mismos. |
| EP4308561A4 (en) * | 2021-05-11 | 2025-01-22 | Yuhan Corporation | COMPOUNDS HAVING INHIBITING ACTIVITY AGAINST GLUCOSYLCERAMIDE SYNTHASE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF |
| WO2023042177A1 (en) | 2021-09-20 | 2023-03-23 | Gt Gain Therapeutics Sa | Enantiomers of 5-((7-chloroisoquinolin-1-yl)amino)-n-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)picolinamide |
| WO2023239892A1 (en) * | 2022-06-10 | 2023-12-14 | Arkuda Therapeutics | Compounds for modulation of cd68 and uses thereof |
| AU2023368362A1 (en) * | 2022-10-24 | 2025-03-20 | Green Cross Corporation | Improved processes for preparing dimethyl-2,3-dihydro-1h-indene derivatives |
| IL319916A (en) * | 2022-10-24 | 2025-05-01 | Yuhan Corp | A new salt of a derivative of dimethyl-3,2-dihydro-1H-indene and processes for its preparation |
| KR20250106321A (ko) | 2022-12-01 | 2025-07-09 | 젠자임 코포레이션 | 강력하거나 중간 수준인 cyp3a4 억제제와 조합한 벤글루스타트 |
| AU2023418678A1 (en) | 2022-12-30 | 2025-07-17 | Gt Gain Therapeutics Sa | Method of treating tauopathies |
| AU2024371889A1 (en) | 2023-11-02 | 2026-04-09 | Gt Gain Therapeutics Sa | Substituted indolyl compounds, compositions thereof, and therapeutic uses thereof |
| KR20250117295A (ko) * | 2024-01-26 | 2025-08-04 | 주식회사유한양행 | 고셔병의 예방 또는 치료용 약제학적 조성물 |
| WO2025215582A1 (en) | 2024-04-11 | 2025-10-16 | Gt Gain Therapeutics Sa | Substituted pyrazolopyridine and pyrazolopyrimidine compounds and their use |
| TW202604489A (zh) | 2024-04-19 | 2026-02-01 | 美商健臻公司 | 用於降低患有神經節苷脂儲積症的患者中的疾病相關生物標誌物水準之方法 |
| WO2025219952A1 (en) | 2024-04-19 | 2025-10-23 | Genzyme Corporation | Venglustat for use in methods for reducing disease related biomarker levels in patients with ganglioside storage disorders |
| WO2025262570A1 (en) | 2024-06-17 | 2025-12-26 | Genzyme Corporation | Venglustat as an inhibitor of glucosylceramide synthase in subjects having hepatic impairment |
| CN118496159B (zh) * | 2024-07-18 | 2024-09-24 | 广州医科大学附属市八医院 | 一种化合物在制备具有预防和/或治疗肝纤维化作用的药物中的应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (enExample) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| AU590995B2 (en) * | 1986-10-03 | 1989-11-23 | Micro Motion, Inc. | Density insensitive coriolis mass flow rate meter |
| IE62231B1 (en) | 1987-12-24 | 1995-01-11 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| US5549892A (en) | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| IT1228293B (it) * | 1989-02-06 | 1991-06-07 | Angeli Inst Spa | Benzoderivati di composti eterociclici contenenti azoto. |
| US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| WO1995021820A1 (en) * | 1994-02-10 | 1995-08-17 | Yamanouchi Pharmaceutical Co., Ltd. | Novel carbamate derivative and medicinal composition containing the same |
| JPH08198751A (ja) * | 1995-01-19 | 1996-08-06 | Yamanouchi Pharmaceut Co Ltd | カルバメート誘導体 |
| US5668144A (en) * | 1995-11-08 | 1997-09-16 | American Home Products Corporation | 1-azabicyclopheptane derivatives |
| US6066626A (en) | 1997-10-29 | 2000-05-23 | Genzyme Corporation | Compositions and method for treating lysosomal storage disease |
| US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| FR2791678B1 (fr) | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique |
| GB0010955D0 (en) * | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| HUP0303529A3 (en) * | 2000-12-22 | 2008-03-28 | Almirall Ag | New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use |
| ES2275808T3 (es) * | 2001-02-06 | 2007-06-16 | Pfizer Products Inc. | Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos. |
| JP2003267977A (ja) * | 2002-03-14 | 2003-09-25 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体 |
| ES2203327B1 (es) * | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
| US7985760B2 (en) * | 2002-07-17 | 2011-07-26 | Actelion Pharmaceuticals Ltd. | Piperidinetriol derivatives as inhibitors of glycosyceramid synthase |
| JPWO2004011430A1 (ja) * | 2002-07-25 | 2005-11-24 | アステラス製薬株式会社 | ナトリウムチャネル阻害剤 |
| SE0202598D0 (sv) * | 2002-09-02 | 2002-09-02 | Astrazeneca Ab | Alpha-7 Nicotinic receptor agonists and statins in combination |
| ES2462545T3 (es) * | 2002-12-06 | 2014-05-23 | The Feinstein Institute For Medical Research | Un procedimiento para la determinación de un agonista colinérgico selectivo para un receptor alfa7 nicotínico |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| JP2007186422A (ja) * | 2004-01-28 | 2007-07-26 | Astellas Pharma Inc | アリールスルフィド誘導体 |
| WO2006002375A2 (en) * | 2004-06-23 | 2006-01-05 | The Feinstein Institute For Medical Research | Method of treating ileus by pharmacological activation of cholinergic receptors |
| JP2008519840A (ja) | 2004-11-10 | 2008-06-12 | ジェンザイム・コーポレイション | 糖尿病の処置方法 |
| WO2007100430A2 (en) * | 2006-01-27 | 2007-09-07 | Yale University | Cytisine and acetylcholine analogs and methods of treating mood disorders |
| US7840109B2 (en) * | 2006-08-14 | 2010-11-23 | Adc Telecommunications, Inc. | Factory spliced cable assembly |
| EP2211856A4 (en) * | 2007-11-29 | 2011-02-09 | Hospital For Sick Children | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDER |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| JP2011529500A (ja) * | 2008-07-28 | 2011-12-08 | ジェンザイム コーポレーション | 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害 |
| WO2010015816A2 (en) * | 2008-08-06 | 2010-02-11 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
| EP2154136A1 (en) * | 2008-08-08 | 2010-02-17 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine carbonate derivatives and medicinal compositions thereof |
| WO2010091104A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
| WO2010091164A1 (en) | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibitors of glucosylceramide synthase |
| US20100242354A1 (en) * | 2009-06-09 | 2010-09-30 | Sundrop Fuels, Inc. | Systems and methods for reactor chemistry and control |
| EP2470199B1 (en) | 2009-08-28 | 2019-05-22 | Icahn School of Medicine at Mount Sinai | Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency |
| CN103917094B (zh) * | 2011-03-18 | 2016-11-09 | 建新公司 | 葡萄糖基神经酰胺合酶抑制剂 |
-
2012
- 2012-03-16 CN CN201280024127.6A patent/CN103917094B/zh active Active
- 2012-03-16 SI SI201231727T patent/SI2685986T1/sl unknown
- 2012-03-16 MX MX2013010710A patent/MX365245B/es active IP Right Grant
- 2012-03-16 TW TW101109086A patent/TWI546301B/zh active
- 2012-03-16 DK DK12760259.7T patent/DK2685986T3/da active
- 2012-03-16 MY MYPI2013003389A patent/MY173998A/en unknown
- 2012-03-16 MX MX2018007961A patent/MX368340B/es unknown
- 2012-03-16 PL PL19207540.6T patent/PL3673906T3/pl unknown
- 2012-03-16 HR HRP20200226TT patent/HRP20200226T1/hr unknown
- 2012-03-16 HU HUE12760259A patent/HUE047888T2/hu unknown
- 2012-03-16 MA MA36299A patent/MA35023B1/fr unknown
- 2012-03-16 ES ES19207540T patent/ES3037907T3/es active Active
- 2012-03-16 ES ES12760259T patent/ES2774293T3/es active Active
- 2012-03-16 KR KR1020137027592A patent/KR101987736B1/ko active Active
- 2012-03-16 CR CR20190034A patent/CR20190034A/es unknown
- 2012-03-16 CN CN201610884699.1A patent/CN107080747B/zh active Active
- 2012-03-16 EP EP19207540.6A patent/EP3673906B1/en active Active
- 2012-03-16 RS RS20200222A patent/RS59963B1/sr unknown
- 2012-03-16 PE PE2013002075A patent/PE20140412A1/es active IP Right Grant
- 2012-03-16 HR HRP20250907TT patent/HRP20250907T1/hr unknown
- 2012-03-16 LT LTEP19207540.6T patent/LT3673906T/lt unknown
- 2012-03-16 AU AU2012231275A patent/AU2012231275A1/en not_active Abandoned
- 2012-03-16 AR ARP120100873 patent/AR085425A1/es active IP Right Grant
- 2012-03-16 PY PY201201212975A patent/PY1212975A/es unknown
- 2012-03-16 BR BR112013023774-0A patent/BR112013023774B1/pt active IP Right Grant
- 2012-03-16 JP JP2013558205A patent/JP6117708B2/ja active Active
- 2012-03-16 FI FIEP19207540.6T patent/FI3673906T3/fi active
- 2012-03-16 PL PL12760259T patent/PL2685986T3/pl unknown
- 2012-03-16 BR BR122019017719-8A patent/BR122019017719B1/pt active IP Right Grant
- 2012-03-16 HU HUE19207540A patent/HUE072576T2/hu unknown
- 2012-03-16 UA UAA201312420A patent/UA118248C2/uk unknown
- 2012-03-16 WO PCT/US2012/029417 patent/WO2012129084A2/en not_active Ceased
- 2012-03-16 PH PH1/2013/501944A patent/PH12013501944A1/en unknown
- 2012-03-16 RU RU2018104472A patent/RU2018104472A/ru not_active Application Discontinuation
- 2012-03-16 SI SI201232091T patent/SI3673906T1/sl unknown
- 2012-03-16 LT LTEP12760259.7T patent/LT2685986T/lt unknown
- 2012-03-16 DK DK19207540.6T patent/DK3673906T3/da active
- 2012-03-16 PT PT192075406T patent/PT3673906T/pt unknown
- 2012-03-16 EP EP12760259.7A patent/EP2685986B1/en active Active
- 2012-03-16 EP EP25169140.8A patent/EP4559918A3/en active Pending
- 2012-03-16 PT PT127602597T patent/PT2685986T/pt unknown
- 2012-03-16 CA CA2830540A patent/CA2830540C/en active Active
- 2012-03-16 UY UY33958A patent/UY33958A/es not_active Application Discontinuation
- 2012-03-16 RS RS20250761A patent/RS67073B1/sr unknown
- 2012-03-16 RU RU2013146550A patent/RU2645675C2/ru active
- 2012-03-16 TW TW105121161A patent/TWI634119B/zh active
-
2013
- 2013-09-17 DO DO2013000209A patent/DOP2013000209A/es unknown
- 2013-09-17 IL IL228514A patent/IL228514B/en active IP Right Grant
- 2013-09-17 CL CL2013002688A patent/CL2013002688A1/es unknown
- 2013-09-17 NI NI201300083A patent/NI201300083A/es unknown
- 2013-09-18 GT GT201300215A patent/GT201300215A/es unknown
- 2013-09-18 ZA ZA2013/07016A patent/ZA201307016B/en unknown
- 2013-09-18 MX MX2019008428A patent/MX2019008428A/es unknown
- 2013-09-18 US US14/030,725 patent/US9139580B2/en active Active
- 2013-10-17 CO CO13246820A patent/CO6801749A2/es active IP Right Grant
- 2013-10-17 EC ECSP13012978 patent/ECSP13012978A/es unknown
-
2014
- 2014-08-28 US US14/471,958 patent/US9126993B2/en active Active
-
2015
- 2015-08-25 US US14/835,402 patent/US20160207933A1/en not_active Abandoned
-
2016
- 2016-10-14 AU AU2016244305A patent/AU2016244305B2/en active Active
-
2017
- 2017-03-22 JP JP2017055577A patent/JP6420860B2/ja active Active
-
2019
- 2019-08-15 US US16/542,166 patent/US20200048266A1/en not_active Abandoned
-
2021
- 2021-04-27 US US17/242,016 patent/US20210261557A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018104472A (ru) | Ингибиторы глюкозилцерамид-синтазы | |
| JP2015527406A5 (enExample) | ||
| KR101472248B1 (ko) | 뒤시엔느 근이영양증의 치료 | |
| JP2013529210A5 (enExample) | ||
| JP2010502730A5 (enExample) | ||
| JP2009263394A5 (enExample) | ||
| PH12012502572A1 (en) | Novel nicotinamide derivative or salt thereof | |
| JP2013510178A5 (enExample) | ||
| AR083542A1 (es) | Piperidin-4-il-azetidin diamidas como inhibidores de monoacilglicerol lipasa | |
| JP2009526830A5 (enExample) | ||
| PE20061198A1 (es) | Derivados de pirazol como inhibidores de cdk y gsk | |
| MX2009010491A (es) | Derivado heterociclico de 5 miembros y su uso para propositos medicos. | |
| JP2011513305A5 (enExample) | ||
| JP2010529147A5 (enExample) | ||
| AR060807A1 (es) | Derivados de arilaminopiridina heteroaril - susutituidos como inhibidores de mek | |
| PT2133332E (pt) | Derivado de (aza)indole e sua utilização para fins médicos | |
| JP2017537940A5 (enExample) | ||
| JP2013509392A5 (enExample) | ||
| PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
| PE20120834A1 (es) | Derivados de furopirimidindiona como moduladores de trpa1 | |
| AR066817A1 (es) | Inhibidores de la glucosilceramida sintasa del tipo 2-acilaminopropanol | |
| NZ593712A (en) | Intermediates for synthesising nucleoside aryl phosphoramidates | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| JP2012530758A5 (enExample) | ||
| JP2013533253A5 (enExample) |